SCHEMBL3663330

SCHEMBL3663330

CCOC(=O)CN(Cc1ccc(OC)cc1OC)Cc1c(-c2ccccc2)noc1C(=O)OCC.CCOC(=O)c1ncc2c(-c3ccccc3)noc2c1O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.38
MAPT P10636 1/20 0.38
ALDH1A1 P00352 3/20 0.36
PKM P14618 1/20 0.36
PPARA Q07869 7/20 0.35
PPARG P37231 6/20 0.35
PPARD Q03181 6/20 0.35
TSHR P16473 2/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
GABRA5 P31644 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660421 0.96 MAPT (0.36) PTPN1MAPTALDH1A1TSHRKDM4E
SCHEMBL3657976 0.94 POLB (0.39) PTPN1MAPTALDH1A1TSHRPOLB
SCHEMBL3660444 0.93 TP53 (0.35) PTPN1MAPTALDH1A1POLBGABRA5
SCHEMBL2777556 0.90 PTPN1 (0.43) PTPN1MAPTALDH1A1PKMTSHR
SCHEMBL3660246 0.88 MEN1 (0.35) PTPN1MAPTALDH1A1TSHRPOLB
SCHEMBL3663664 0.87 PTPN1 (0.41) PTPN1MAPTALDH1A1PKMTSHR
SCHEMBL2779106 0.85 POLB (0.41) PTPN1MAPTALDH1A1TSHRKDM4E
SCHEMBL2776138 0.83 POLB (0.47) PTPN1MAPTALDH1A1PKMTSHR
SCHEMBL2777595 0.82 TP53 (0.39) PTPN1MAPTALDH1A1PKMTSHR
SCHEMBL2776688 0.78 MEN1 (0.42) PTPN1MAPTALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed